Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Just For You
The Cannabis Sector's Billion-Dollar Tax CutReported by Jeffrey Neal Johnson. Published: 4/23/2026. 
Key Points
- A major administrative policy shift is normalizing the tax structure for the cannabis industry, directly enhancing the financial standing of licensed operators.
- The largest multi-state operators are now positioned to leverage their significant revenues to generate substantial free cash flow for growth and expansion.
- This financial normalization shifts the investment focus from speculative policy hopes toward the tangible business fundamentals of established market leaders.
- Special Report: Elon Musk’s $1 Quadrillion AI IPO
On the heels of the executive order to fast-track research into psychedelic drugs, a second major federal policy shift on April 23, 2026, is sending waves through the cannabis sector. But the real catalyst is being widely misunderstood on Wall Street. The administration’s decision to move state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act is not federal legalization. Instead, the key development is a surgical change in the U.S. tax code that could unlock billions in value for a select group of companies. For investors, this move rewrites the industry's playbook—shifting it from an era of speculative hope to one focused on tangible cash flow. It creates a clearer framework for identifying potential profitability in the cannabis market. How the Death of 280E Changes Everything
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itself - it's the infrastructure behind it.
One small-cap company supplies a mission-critical component to Musk's xAI Colossus site that can't be built around. While retail waits for a ticker that doesn't exist yet, early money is moving into this supplier at a fraction of its potential value. See the small-cap stock powering the SpaceX buildout today
For more than a decade, U.S. cannabis companies have been uniquely burdened by Internal Revenue Code Section 280E. This tax rule—designed in the 1980s to prevent illegal drug traffickers from claiming business deductions—was applied to state-legal cannabis businesses. Put simply, licensed operators could not deduct ordinary and necessary business expenses from taxable income. Imagine a typical retail business being barred from deducting rent, payroll or marketing. That policy forced cannabis operators to pay taxes on gross profit rather than net income, producing crushing effective tax rates that often exceeded 70%. The administrative reclassification to Schedule III immediately removes this constraint for licensed medical operators. That single change allows them to be taxed like other businesses, reducing their effective rate toward the standard corporate rate of roughly 21%. The valuation impact is direct and powerful. This policy change functions as a large, non-dilutive infusion of cash onto company balance sheets: it should boost net income, increase earnings per share (EPS), and free up hundreds of millions in capital that management can use to grow the business, pay down debt or return capital to shareholders instead of sending it to the IRS. The New Kings of Cannabis Cash FlowDespite sector-wide excitement, this fiscal windfall will not lift all companies equally. While Schedule III represents a broad administrative shift, the most meaningful benefit—significant, non-dilutive liquidity—is likely to accrue primarily to leading U.S. multi-state operators (MSOs) with dominant revenue streams and strong operating platforms. The Profitability KingGreen Thumb Industries (OTCMKTS: GTBIF) stands out. It was one of the few major MSOs to consistently report positive net income even under the full weight of 280E, with trailing net income of $114.15 million. With a reasonable price-to-earnings ratio (P/E) near 15x before the change, Green Thumb’s profitability should expand significantly. That incremental cash flow could be reinvested in marketing its consumer brands—such as Rythm and Dogwalkers—or used to accelerate market-share gains in key states. The Scale and Shareholder-Return PlayWith more than $1.27 billion in annual sales, Curaleaf (OTCMKTS: CURLF) has scale that could translate into some of the largest tax savings in the industry. The company underscored this new reality by announcing an $83 million share buyback program. A buyback is a classic move for a mature company with excess cash. That Curaleaf announced it days before the policy shift may signal management’s confidence even before the official end of the 280E cash drain. It suggests the company is shifting from survival mode toward returning capital to shareholders—an attractive narrative for value-oriented investors. The High-Leverage and Strategic Plays: Trulieve, Verano, and Cresco LabsOther MSOs appear positioned to deploy their tax savings for aggressive growth. Trulieve Cannabis (OTCMKTS: TCNNF), with dominant share in Florida and strong political ties, could use the savings to fortify its lead ahead of any adult-use legalization ballot measure. Similarly, Cresco Labs (OTCMKTS: CRLBF), which recently obtained a medical license in Texas, and Verano Holdings (OTCMKTS: VRNOF), which streamlined its structure by redomiciling to Nevada, now have the capital to fund expansion without taking on as much debt or diluting existing shareholders. The Tilray Contrast: Know What You OwnWhen cannabis hits the headlines, many investors gravitate to familiar, NASDAQ-listed names like Tilray Brands, Inc. (NASDAQ: TLRY), assuming OTC names are too risky. Tilray is one of the most liquid and widely held stocks in the space and is a natural choice for traders seeking sector exposure. But Tilray’s business model differs materially from U.S. MSOs. Its operations focus on the Canadian adult-use market, international medical markets in Europe, and a growing U.S. presence centered on brands such as SweetWater Brewing. Because Tilray was not subject to the punitive U.S. 280E tax, it does not receive the direct financial uplift from this specific regulatory change. For investors assessing the policy’s impact, Tilray is more likely a sympathy trade—benefiting from positive sector sentiment—rather than a primary beneficiary of the tax reclassification. The Green Wave: A New Era for Cannabis ProfitsThe move to Schedule III is a partial win, but it may represent the most important financial victory the U.S. cannabis industry could have hoped for. It does not legalize cannabis federally, enable interstate commerce, or automatically clear the path for uplisting to major U.S. exchanges like NASDAQ—those remain significant hurdles. Still, by normalizing the industry's tax structure, the change gives the strongest U.S. operators the ability to build substantial internal capital. The need for federal banking reform remains important, but it is less urgent now that these companies can generate the cash needed to fund operations and expansion. The investment playbook has shifted. The focus should move away from broad speculation on policy reform toward fundamental analysis of MSOs that can convert large tax savings into sustainable earnings and shareholder returns. While the industry hasn’t received a full legal all‑clear, it has received an official financial one. Investors interested in the sector may want to add the top U.S. MSOs to their watchlists and watch upcoming quarterly reports for management’s first guidance in this post‑280E environment. |
Post a Comment
0Comments